Welcome to our dedicated page for NORTHWEST BIOTHRPUTCS news (Ticker: NWBO), a resource for investors and traders seeking the latest updates and insights on NORTHWEST BIOTHRPUTCS stock.
Northwest Biotherapeutics develops DCVax® personalized immune therapies for solid tumor cancers. News about NWBO centers on its dendritic cell-based cancer vaccine platform, including DCVax-L for glioblastoma and DCVax-Direct for inoperable solid tumors, along with scientific presentations on next-generation dendritic cell treatments.
Company updates also cover manufacturing and treatment-logistics capacity for cell therapies, including the Sawston, UK facility, leukapheresis services, and the completed acquisition of Advent BioServices as a wholly owned subsidiary. Other recurring developments include clinical and regulatory communications, financing arrangements, capital-structure matters, operating results, and governance changes.
Northwest Biotherapeutics (OTCQB: NWBO) has entered into a non-binding Memorandum of Understanding with Saudi Pharmaceutical Industries and Medical Appliance Company (SPIMACO) to pursue a collaboration to bring DCVax-L for glioblastoma to Saudi Arabia under a contemplated revenue-sharing model.
According to Northwest Biotherapeutics, SPIMACO would interface with the Saudi Food and Drug Authority and be expected to act as commercial partner for marketing, sales and distribution, while the company supplies DCVax-L, provides regulatory data and scientific support, and retains all intellectual property. The MOU also contemplates negotiating license and technology transfer agreements to enable localized manufacturing in Saudi Arabia and possible future expansion to other indications and GCC countries. Northwest Biotherapeutics notes it has completed a 331-patient Phase III DCVax-L trial for glioblastoma, published results in JAMA Oncology, and has a marketing authorization application under review in the UK.
Northwest Biotherapeutics (OTCQB:NWBO) reported updated Phase III survival data for DCVax-L in glioblastoma using individual patient-level data and multiple independent analyses.
Propensity score matching showed a 3.4–6.3 month median survival advantage (HR 0.69–0.77, p=0.004–0.027); inverse probability weighting showed 3.4–4.3 months, all exceeding the original 2.8‑month cohort-level result. Sensitivity analyses (E Values, Rosenbaum's Gamma) suggested limited impact from unknown confounders. A 331‑patient Phase III trial is completed and an MAA for DCVax‑L in the UK remains under review.
Northwest Biotherapeutics (OTCQB:NWBO) announced that Chief Technical Officer Dr. Marnix Bosch will present “DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses” at the 2026 British Neuro-Oncology Society meeting on July 3 at 10:00 a.m. GMT.
The talk will address DCVax-L treatment and patient survival using propensity score matching. A slide deck will be posted on the company’s website. Northwest Biotherapeutics is developing DCVax-L for glioblastoma, supported by a completed 331-patient Phase III trial, JAMA Oncology publication, and a UK marketing authorization application under review.
Northwest Biotherapeutics (OTCQB:NWBO) appointed Dr. Annalisa Jenkins, OBE as Strategic Adviser to support development and expansion of its DCVax® dendritic cell cancer vaccine platform. Dr. Jenkins brings 25+ years of biopharma leadership and commercial experience.
The company has submitted a Marketing Authorization Application (MAA) to the UK MHRA for DCVax®-L in glioblastoma, completed a 331-patient Phase III trial with results published in JAMA Oncology, and finished a 40-patient Phase I trial of DCVax®-Direct with Phase II planned.
Northwest Biotherapeutics (OTCQB:NWBO) is establishing a dedicated leukapheresis clinic at The London Welbeck Hospital to address UK capacity shortages and support scale-up of its DCVax programs. The company began equipment purchases in Q4 2025, expects buildout completion by June, has received one machine, and is pursuing license applications.
The Welbeck clinic will offer procedures about four hours long, capacity for 4 patients per day, potential extended hours/weekends, and may provide services to third parties.
Northwest Biotherapeutics (OTCQB:NWBO) has begun on-site construction of the first Grade C manufacturing suite at its Sawston, UK facility. The company says the new Grade C suite will more than double the aggregate capacity of its existing Grade B suites and is viewed as a major step toward large-scale production of DCVax products.
The project timeline targets establishing manufacturing in the Grade C suite in Q2 2026, with construction taking about six months, followed by equipment installation and validation. Equipment costs are described as several million pounds, with individual machines noted at about £800,000 each new.
Northwest Biotherapeutics (OTCQB:NWBO) announced on October 24, 2025 that its acquisition of Advent BioServices Ltd. has closed and Advent is now a wholly owned subsidiary.
The deal transfers Advent's fixed assets, cryostorage equipment, intellectual property and intangibles to NWBio; 19 million NWBio securities previously issued to Advent (13.5M shares and 5.5M options) are reverting back to the company. Consideration includes £1.4 million plus the net accounts payable due to Advent, payable in installments over two years with possible acceleration after regulatory approval of DCVax-L. The company expects operational consolidation, GMP facility closure in London, reallocation to Sawston and U.S. capacity development, and manufacturing scale-up.
Northwest Biotherapeutics (OTCQB:NWBO), a biotechnology company developing DCVax® immunotherapies, has announced an agreement to acquire Advent BioServices Ltd. from Toucan Holdings LLC. The acquisition will make Advent a wholly-owned subsidiary, enabling fully integrated operations and enhanced scale-up potential.
Key transaction details include: recovery of 19 million NWBio securities previously issued to Advent, acquisition of fixed assets including cryostorage equipment, and consideration payments over two years including £1.4 million plus net accounts payable. The deal aims to consolidate operations at London and Sawston GMP facilities, focusing on manufacturing ramp-up following completion of product development work for the MAA and DCVax®-Direct program.
Northwest Biotherapeutics (OTCQB:NWBO), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, has announced the passing of its Senior Vice President and General Counsel, Mr. Les Goldman, due to a stroke.
The company, which focuses on developing personalized immunotherapy products, has completed a 331-patient Phase III trial of DCVax-L for glioblastoma (GBM) and submitted a MAA for commercial approval in the UK. Additionally, NWBO has completed a 40-patient Phase I trial of DCVax-Direct for inoperable solid tumor cancers and plans to pursue Phase II trials this year.